JPWO2022068877A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022068877A5 JPWO2022068877A5 JP2023519416A JP2023519416A JPWO2022068877A5 JP WO2022068877 A5 JPWO2022068877 A5 JP WO2022068877A5 JP 2023519416 A JP2023519416 A JP 2023519416A JP 2023519416 A JP2023519416 A JP 2023519416A JP WO2022068877 A5 JPWO2022068877 A5 JP WO2022068877A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- amorphous solid
- solid dispersion
- palbociclib
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002253 acid Substances 0.000 claims 32
- 239000007962 solid dispersion Substances 0.000 claims 24
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims 20
- 229960004390 palbociclib Drugs 0.000 claims 16
- 239000008186 active pharmaceutical agent Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 6
- 239000000463 material Substances 0.000 claims 6
- 150000007524 organic acids Chemical class 0.000 claims 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 6
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 4
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 claims 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 239000011975 tartaric acid Substances 0.000 claims 3
- 235000002906 tartaric acid Nutrition 0.000 claims 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- 235000011054 acetic acid Nutrition 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 2
- 235000015165 citric acid Nutrition 0.000 claims 2
- 229920001531 copovidone Polymers 0.000 claims 2
- 229960005215 dichloroacetic acid Drugs 0.000 claims 2
- 239000001530 fumaric acid Substances 0.000 claims 2
- 235000011087 fumaric acid Nutrition 0.000 claims 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims 2
- 239000004310 lactic acid Substances 0.000 claims 2
- 235000014655 lactic acid Nutrition 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
- 239000011976 maleic acid Substances 0.000 claims 2
- 239000001630 malic acid Substances 0.000 claims 2
- 235000011090 malic acid Nutrition 0.000 claims 2
- 229940098779 methanesulfonic acid Drugs 0.000 claims 2
- 235000006408 oxalic acid Nutrition 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims 2
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- -1 acetate-polyethylene Chemical group 0.000 claims 1
- ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 239000003463 adsorbent Substances 0.000 claims 1
- 150000001450 anions Chemical class 0.000 claims 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims 1
- 229940092714 benzenesulfonic acid Drugs 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- QDHFHIQKOVNCNC-UHFFFAOYSA-N butane-1-sulfonic acid Chemical compound CCCCS(O)(=O)=O QDHFHIQKOVNCNC-UHFFFAOYSA-N 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229920000578 graft copolymer Polymers 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 229940045996 isethionic acid Drugs 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- OPUAWDUYWRUIIL-UHFFFAOYSA-N methanedisulfonic acid Chemical compound OS(=O)(=O)CS(O)(=O)=O OPUAWDUYWRUIIL-UHFFFAOYSA-N 0.000 claims 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims 1
- NIXKBAZVOQAHGC-UHFFFAOYSA-N phenylmethanesulfonic acid Chemical compound OS(=O)(=O)CC1=CC=CC=C1 NIXKBAZVOQAHGC-UHFFFAOYSA-N 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229940069328 povidone Drugs 0.000 claims 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 claims 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 claims 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011046895.4A CN114306245A (zh) | 2020-09-29 | 2020-09-29 | 无定形固体分散体的药物组合物及其制备方法 |
| CN202011046895.4 | 2020-09-29 | ||
| PCT/CN2021/121696 WO2022068877A1 (en) | 2020-09-29 | 2021-09-29 | Pharmaceutical compositions of amorphous solid dispersions and methods of preperation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023543814A JP2023543814A (ja) | 2023-10-18 |
| JPWO2022068877A5 true JPWO2022068877A5 (enrdf_load_stackoverflow) | 2024-10-04 |
Family
ID=80822203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023519416A Pending JP2023543814A (ja) | 2020-09-29 | 2021-09-29 | 非晶質固体分散体の医薬組成物およびその調製方法 |
Country Status (9)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023239642A1 (en) | 2022-03-25 | 2024-11-07 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical compositions of protac compounds and uses thereof |
| WO2023239336A1 (en) * | 2022-06-08 | 2023-12-14 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | A pharmaceutical composition comprising palbociclib |
| WO2023239337A1 (en) * | 2022-06-08 | 2023-12-14 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | A pharmaceutical composition comprising palbociclib |
| EP4302832A1 (en) * | 2022-07-07 | 2024-01-10 | Lotus Pharmaceutical Co., Ltd. | Palbociclib formulation containing glucono delta lactone |
| WO2024186765A1 (en) * | 2023-03-03 | 2024-09-12 | Aems Corp. | Amorphous solid composition, methods and uses thereof |
| CN116473923B (zh) * | 2023-05-29 | 2024-05-14 | 杭州剂泰医药科技有限责任公司 | 一种奈拉替尼固体分散体组合物及其制备方法和应用 |
| KR20250062261A (ko) | 2023-10-30 | 2025-05-08 | 신풍제약주식회사 | 향상된 용해도 및 안정성을 가지는 팔보시클립의 제약학적 조성물 및 이의 제조방법 |
| WO2025154730A1 (ja) * | 2024-01-18 | 2025-07-24 | 沢井製薬株式会社 | 固体分散体、固体分散体を含む製剤、及び固体分散体の製造方法 |
| WO2025213381A1 (en) * | 2024-04-10 | 2025-10-16 | Hangzhou Jitai Pharmaceutical Technology Co., Ltd | Neratinib-cyclodextrin composition and method for preparing same |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US745168A (en) | 1903-07-16 | 1903-11-24 | Arthur C Eastwood | System for control of electric motors. |
| US6087380A (en) | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
| EP0198395A3 (en) | 1985-04-09 | 1989-04-12 | Mitsubishi Kasei Corporation | Separating agent for mixed solution |
| US4847092A (en) | 1985-11-12 | 1989-07-11 | Eli Lilly And Company | Orally administerable sustained release pharmaceutical formulations |
| ATE238266T1 (de) | 1998-06-03 | 2003-05-15 | Gergely Dr & Co | Mit alkali- bzw. erdalkali-ionen dotierte zitronensäure |
| JP2000309588A (ja) | 1999-04-28 | 2000-11-07 | Taisho Pharmaceut Co Ltd | 固体分散体 |
| EA003052B1 (ru) | 1999-07-27 | 2002-12-26 | Балканфарма Холдинг АД | Антиаритмическое лекарственное средство |
| WO2001055148A1 (en) | 2000-01-27 | 2001-08-02 | Warner-Lambert Company | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease |
| ES2311532T3 (es) | 2000-08-04 | 2009-02-16 | Warner-Lambert Company Llc | 2-(4-pirdil)amino-6-dialcoxifenil-pirido(2.3-d)pirimidin-7-onas. |
| US20050019399A1 (en) | 2001-09-21 | 2005-01-27 | Gina Fischer | Controlled release solid dispersions |
| BR122016021801B8 (pt) | 2002-01-22 | 2021-05-25 | Warner Lambert Co | compostos 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas |
| NZ535663A (en) | 2002-03-07 | 2006-06-30 | Boehringer Ingelheim Pharma | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester and the salts thereof |
| DE10209985A1 (de) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma | Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propinsäure-ethylester und dessen Salze |
| US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| US7884127B2 (en) | 2002-07-08 | 2011-02-08 | Pirimal Life Sciences Ltd. | Inhibitors of cyclin dependent kinases and their use |
| AU2004255934B2 (en) | 2003-07-11 | 2010-02-25 | Warner-Lambert Company Llc | Isethionate salt of a selective CDK4 inhibitor |
| GB0317663D0 (en) | 2003-07-29 | 2003-09-03 | Astrazeneca Ab | Pharmaceutical composition |
| DE10339862A1 (de) | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
| DE102004062864A1 (de) | 2004-12-21 | 2006-06-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Folienbehälter |
| CN113952338A (zh) | 2005-02-03 | 2022-01-21 | 综合医院公司 | 治疗吉非替尼耐药性癌症的方法 |
| KR100627687B1 (ko) | 2005-04-20 | 2006-09-25 | 주식회사 씨티씨바이오 | 시부트라민 유리염기 함유 조성물 및 이의 제조방법 |
| WO2006112649A1 (en) | 2005-04-20 | 2006-10-26 | Ctc Bio, Inc. | Pharmaceutical composition containing sibutramine free base and manufacturing method thereof |
| US20090214645A1 (en) | 2005-08-22 | 2009-08-27 | Andrea Kramer | Pharmaceutical compositions comprising a ph-dependent drug, a ph modifier and a retarding agent |
| ES2533563T5 (es) | 2006-01-27 | 2018-07-24 | Adare Pharmaceuticals, Inc. | Sistemas de suministro de fármacos que comprenden fármacos débilmente básicos y ácidos orgánicos |
| WO2009014642A1 (en) | 2007-07-19 | 2009-01-29 | Amgen Inc. | Combination of a de novo purine biosynthesis inhibitor and a cyclin dependent kinase inhibitor for the treatment of cancer |
| WO2009042114A2 (en) | 2007-09-21 | 2009-04-02 | The Johns Hopkins University | Phenazine derivatives and uses thereof |
| WO2009061345A2 (en) | 2007-11-07 | 2009-05-14 | Cornell Research Foundation, Inc. | Targeting cdk4 and cdk6 in cancer therapy |
| AU2009298367A1 (en) | 2008-10-01 | 2010-04-08 | The University Of North Carolina At Chapel Hill | Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors |
| WO2010055119A2 (en) | 2008-11-17 | 2010-05-20 | Novartis Ag | Pharmaceutical composition comprising pimobendan |
| DE102009028354B4 (de) | 2009-08-07 | 2013-05-29 | Mtu Friedrichshafen Gmbh | Gasführungssystem für eine Peripherie einer Brennkraftmaschine zur Führung von Gas der Brennkraftmaschine, Brennkraftsystem und Verfahren zum Betrieb der Brennkraftmaschine |
| JP2013511549A (ja) | 2009-11-20 | 2013-04-04 | インフィニティー ファーマシューティカルズ， インコーポレイテッド | ヘッジホッグ関連癌の治療のための方法及び組成物 |
| CN102106807B (zh) | 2009-12-29 | 2013-03-27 | 上海中西制药有限公司 | 一种固体制剂的制备方法及所得固体制剂 |
| CN102106806B (zh) | 2009-12-29 | 2013-04-17 | 上海中西制药有限公司 | 一种固体制剂的制备方法及所得固体制剂 |
| AR079944A1 (es) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
| UY33227A (es) | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina como inhibidores de la cdk4/6 |
| PE20130231A1 (es) | 2010-06-09 | 2013-04-04 | Abbvie Bahamas Ltd | Dispersiones solidas del compuesto n-(4-{4-amino-7-[1-(2-hidroxietil)-1h-pirazol-4-il]tieno[3,2-c]piridin-3-il}fenil)-n'-(3-fluorofenil)urea |
| AR086913A1 (es) | 2011-06-14 | 2014-01-29 | Novartis Ag | 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas |
| AR088936A1 (es) | 2011-11-23 | 2014-07-16 | Novartis Ag | Formulaciones farmaceuticas |
| WO2014011398A1 (en) | 2012-07-09 | 2014-01-16 | Novartis Ag | Biomarkers associated with cdk inhibitors |
| US20140220112A1 (en) | 2013-02-01 | 2014-08-07 | Zoneone Pharma, Inc. | Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes |
| PL3431475T3 (pl) | 2013-02-21 | 2021-09-13 | Pfizer Inc. | Stałe postacie selektywnego inhibitora CDK4/6 |
| EP2986740B1 (en) | 2013-04-16 | 2020-01-15 | Memorial Sloan-Kettering Cancer Center | Companion diagnostic for cdk4 inhibitors |
| CN111012756B (zh) | 2013-06-21 | 2023-06-13 | 四川海思科制药有限公司 | 一种达比加群酯药物组合物及其制备方法 |
| KR102736746B1 (ko) | 2013-08-14 | 2024-12-03 | 노파르티스 아게 | 암의 치료를 위한 조합 요법 |
| CA2929181A1 (en) | 2013-11-13 | 2015-05-21 | Novartis Ag | Mtor inhibitors for enhancing the immune response |
| US20170067116A1 (en) | 2014-03-04 | 2017-03-09 | The Regents Of The University Of California | Biomarkers of Response to Cyclin D-CDK4/6 Targeted Therapies in Cancer |
| WO2015160986A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| PT3154512T (pt) | 2014-05-01 | 2019-10-30 | Hermes Arzneimittel Gmbh | Formulações orais sólidas compreendendo dispersões fundidas sólidas de ácidos orgânicos em xilitol |
| EP3172214B1 (en) | 2014-07-26 | 2020-05-13 | Sunshine Lake Pharma Co., Ltd. | 2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof |
| CN105616419A (zh) | 2014-11-07 | 2016-06-01 | 江苏豪森药业集团有限公司 | 含有细胞周期蛋白抑制剂固体分散体的药物组合物及其制备方法 |
| CN105616418A (zh) | 2014-11-07 | 2016-06-01 | 江苏豪森药业集团有限公司 | 含有细胞周期蛋白抑制剂的药物制剂及其制备方法 |
| CN104434809B (zh) | 2014-12-10 | 2018-10-16 | 北京科莱博医药开发有限责任公司 | 一种奥拉帕尼固体分散体制剂及其制备方法 |
| EP3255046B1 (en) | 2015-02-03 | 2019-11-27 | Jiangsu Hengrui Medicine Co., Ltd. | Hydroxyethyl sulfonate of cyclin-dependent protein kinase inhibitor, crystalline form thereof and preparation method therefor |
| CZ201589A3 (cs) | 2015-02-11 | 2016-08-24 | Zentiva, K.S. | Pevné formy soli Palbociclibu |
| WO2016156070A1 (en) | 2015-04-02 | 2016-10-06 | Sandoz Ag | Modified particles of palbociclib |
| CN104887641B (zh) | 2015-04-08 | 2017-12-01 | 上海鲁源医药科技有限公司 | 帕布昔利布胃漂浮片及其制备方法 |
| PE20180395A1 (es) | 2015-06-04 | 2018-02-28 | Pfizer | Formas de dosificacion solidas de palbociclib |
| CN105085517B (zh) | 2015-08-06 | 2016-11-23 | 天津华洛康生物科技有限公司 | 一种结晶型帕博西尼游离碱水合物及其制备方法 |
| CN107510847A (zh) | 2016-06-16 | 2017-12-26 | 常州方楠医药技术有限公司 | 一种含有无定型帕博西林固体分散体的药用组合物及其制备方法 |
| WO2017036390A1 (zh) | 2015-09-01 | 2017-03-09 | 上海方楠生物科技有限公司 | 帕博西林或其药学上可接受的盐与药用辅料的组合物及其制备方法 |
| CN106474129A (zh) | 2015-09-01 | 2017-03-08 | 上海方楠生物科技有限公司 | 一种帕博西林或其药学上可接受的盐与药用辅料的组合物及其制备方法 |
| CN105213322A (zh) | 2015-10-30 | 2016-01-06 | 南京正大天晴制药有限公司 | 一种干法制粒工艺制备的药物组合物 |
| CN106831710A (zh) | 2015-12-07 | 2017-06-13 | 常州爱诺新睿医药技术有限公司 | 一种无定型来那替尼或其药学上可接受的盐与药用辅料的固体分散体及其制备方法 |
| WO2017115315A1 (en) | 2015-12-30 | 2017-07-06 | Dr. Reddy's Laboratories Limited | Solid forms of palbociclib |
| CN106967061A (zh) | 2016-01-13 | 2017-07-21 | 常州方楠医药技术有限公司 | 帕博西林的盐、晶型及其制备方法 |
| WO2017130219A1 (en) * | 2016-01-25 | 2017-08-03 | Mylan Laboratories Limited | Amorphous solid dispersion of palbociclib |
| CA3011949A1 (en) | 2016-03-15 | 2017-09-21 | Merrimack Pharmaceuticals, Inc. | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody |
| WO2017172734A1 (en) | 2016-03-29 | 2017-10-05 | Mayo Foundation For Medical Education And Research | Treating cancer metastasis |
| US10449195B2 (en) * | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
| CN109078006B (zh) * | 2016-03-29 | 2021-04-20 | 深圳市药欣生物科技有限公司 | 一种帕布昔利布的药物制剂及其制备方法 |
| CN105748435B (zh) | 2016-04-21 | 2019-03-29 | 石家庄海瑞药物科技有限公司 | 一种帕布昔利布药物组合物及其制备方法 |
| EP3458604B1 (en) | 2016-05-18 | 2021-04-14 | Université Libre de Bruxelles | Method for determining sensitivity to a cdk4/6 inhibitor |
| EP3255048A1 (en) | 2016-06-07 | 2017-12-13 | K.H.S. Pharma Holding GmbH | Non-crystalline form of palbociclib |
| WO2018093484A1 (en) | 2016-10-11 | 2018-05-24 | Duke University | Lasofoxifene treatment of er+ breast cancer |
| CN108017629A (zh) | 2016-11-04 | 2018-05-11 | 上海奥博生物医药技术有限公司 | 一种帕博西尼无定形态 |
| CN106667952A (zh) | 2016-12-12 | 2017-05-17 | 河南润弘制药股份有限公司 | 一种帕布昔利布药物组合物及其制备方法 |
| WO2018191950A1 (en) | 2017-04-21 | 2018-10-25 | Alnova Pharmaceuticals, Ltd. | Palbociclib compositions and methods thereof |
| CN108864078B (zh) | 2017-05-10 | 2021-10-15 | 江苏豪森药业集团有限公司 | 帕博西尼晶型b的制备方法 |
| WO2019056163A1 (zh) | 2017-09-19 | 2019-03-28 | 浙江华海药业股份有限公司 | N-甲酰基帕博西尼及其制备方法和用途以及帕博西尼制剂及其质量控制方法 |
| CN108014343A (zh) | 2017-12-21 | 2018-05-11 | 孟斯琴 | 一种治疗乳腺癌的药物组合物及其制备方法 |
| CN108066312B (zh) | 2017-12-29 | 2020-03-20 | 山东裕欣药业有限公司 | 一种帕博西尼药物组合物及其制备方法 |
| CN108066303A (zh) | 2017-12-31 | 2018-05-25 | 湖南博隽生物医药有限公司 | 一种抗癌药物组合物及其制备方法 |
| JP7698418B2 (ja) | 2018-03-13 | 2025-06-25 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｅｇｆｒ活性化変異を有するがんを治療するための方法 |
| CN108272754A (zh) | 2018-04-11 | 2018-07-13 | 吴小戈 | 一种抗癌药物固体分散体组合物及其制备方法 |
| EP4309656A3 (en) | 2018-05-14 | 2024-02-28 | Pfizer Inc. | Oral solution formulation |
| CN108653222A (zh) | 2018-07-03 | 2018-10-16 | 威海贯标信息科技有限公司 | 一种帕博西尼片剂组合物 |
-
2020
- 2020-09-29 CN CN202011046895.4A patent/CN114306245A/zh not_active Withdrawn
- 2020-11-13 US US17/097,789 patent/US11471418B2/en active Active
-
2021
- 2021-09-29 WO PCT/CN2021/121696 patent/WO2022068877A1/en not_active Ceased
- 2021-09-29 AU AU2021351818A patent/AU2021351818A1/en not_active Abandoned
- 2021-09-29 CA CA3194010A patent/CA3194010A1/en active Pending
- 2021-09-29 US US18/028,651 patent/US20240335390A9/en active Pending
- 2021-09-29 EP EP21874532.1A patent/EP4221691A4/en active Pending
- 2021-09-29 JP JP2023519416A patent/JP2023543814A/ja active Pending
- 2021-09-29 MX MX2023003689A patent/MX2023003689A/es unknown
- 2021-09-29 CN CN202180076133.5A patent/CN116847831A/zh active Pending
- 2021-09-29 KR KR1020237014222A patent/KR20230097027A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100056493A1 (en) | Modified release pharmaceutical composition and a process of making the same | |
| CZ281697B6 (cs) | Farmaceutický prostředek pro perorální podání | |
| JPWO2022068877A5 (enrdf_load_stackoverflow) | ||
| US8968776B2 (en) | Composition comprising a benzimidazole and process for its manufacture | |
| KR20030079766A (ko) | 항진균 포뮬레이션, 그의 제조 방법 및 사용 방법 | |
| KR102727681B1 (ko) | 덱스란소프라졸 또는 이의 약학적으로 허용 가능한 염을 함유하는 안정한 경구투여용 약학 제제 | |
| JP2022174317A5 (enrdf_load_stackoverflow) | ||
| US20120135079A1 (en) | Modified Release Tranexamic Acid Formulation | |
| TWI592154B (zh) | Allisartan-based solid dispersions and pharmaceutical compositions containing the solid dispersions | |
| EP2799072A1 (en) | Solid pharmaceutical composition comprising an antibiotic from the quinolone family and method for the production thereof | |
| JP2017518985A (ja) | アリサルタン・イソプロキシル固体分散体及び医薬組成物 | |
| CN101854921B (zh) | 用于口服施用ppi的药物制剂 | |
| CN116036079A (zh) | 一种复合物的药物组合物及其制备方法 | |
| US20090280173A1 (en) | Multilayer Omeprazole Tablets | |
| US20090280175A1 (en) | Multilayer Proton Pump Inhibitor Tablets | |
| WO2022115056A1 (en) | Sustained release formulation compositions comprising propiverine | |
| CN100525769C (zh) | 一种雷替曲塞缓释制剂及其制备方法 | |
| KR101460783B1 (ko) | 안정성이 개선된 칸데사르탄 실렉세틸을 함유하는 약제학적 조성물 및 이의 제조방법 | |
| JPWO2022055880A5 (enrdf_load_stackoverflow) | ||
| RU2260431C2 (ru) | Лекарственная форма, обладающая антиангинальным действием, и способ ее изготовления | |
| TWI901795B (zh) | 鹽酸決奈達隆藥物組合物、其製備方法及應用 | |
| US20050118265A1 (en) | Antifungal oral dosage forms and the methods for preparation | |
| JPWO2021188695A5 (enrdf_load_stackoverflow) | ||
| CN114377148B (zh) | 盐酸决奈达隆药物组合物、其制备方法及应用 | |
| KR102604761B1 (ko) | 도네페질 및 메만틴을 포함하는 복합 제제 |